The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian
Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study

J 2024

The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study

PRESL, Jiri; Pavel HAVELKA; Vít WEINBERGER; Petra OVESNÁ; Peter FEKETE et al.

Základní údaje

Originální název

The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study

Autoři

Vydání

Cancers, BASEL, MDPI, 2024, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.400

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00137803

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

ovarian cancer; tumor markers; CA125; HE4; recurrence detection

Štítky

14110212, 14110240, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 11. 2024 10:07, Mgr. Tereza Miškechová

Anotace

V originále

Background: Ovarian, fallopian tube, and primary peritoneal cancers often share clinical characteristics and are typically diagnosed at advanced stages due to nonspecific symptoms. The utility of tumor markers, particularly CA125 and HE4, in the diagnosis and follow-up of these cancers remains an area of active investigation. Objectives: The CEEGOG (Central and Eastern European Gynecologic Oncology Group) OX-01 study aimed to evaluate HE4's role alongside CA125 in follow-up for advanced-stage ovarian, fallopian tube, and primary peritoneal cancers. It assessed the potential for detecting recurrence using marker elevation and imaging methods, examining the necessity of dynamic monitoring and current cut-off values' accuracy for early relapse detection. Methods: In this multicenter prospective cohort study, 117 eligible patients with Stage III-IV cancers were included. Patients had elevated CA125 or HE4 at diagnosis and achieved complete remission after first-line treatment. HE4 and CA125 levels were monitored every 3-4 months in the first two years and every six months thereafter. CT scans were performed if markers exceeded set thresholds or increased by over 20%. Results: During a median follow-up of 13.7 months, 73% of patients relapsed. Median HE4 levels were significantly higher in relapsed patients. A 10 IU/mL increase from baseline in CA125 had a sensitivity of 83% and specificity of 93%, while a 15 pmol/L increase in HE4 had a sensitivity of 74% and specificity of 92% for predicting relapse up to three months before CT scan detection. Conclusions: The study found that dynamic changes in HE4 and CA125 levels, rather than predefined cut-off values, are crucial for early relapse detection. These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.

Citovat

PRESL, Jiri; Pavel HAVELKA; Vít WEINBERGER; Petra OVESNÁ; Peter FEKETE; Filip FRUHAUF; Marcin JEDRYKA; Branislav BYSTRICKY; Aleksandra STROJNA; Nataliya VOLODKO; Olga MATYLEVICH; Petra HERBOLTOVA; Pawel BLECHARZ; Vladimir KALIST; Lucie EHRLICHOVÁ; Petr STRANIK; Ladislav MASAK; Renata PONCOVA; Andrzej CZEKANSKI; Barbora CHALOUPKOVA; Michaela KOBLIZKOVA; Vendula SMOLIGOVA; Marketa HRABALOVA; Alena JAKSICOVA; Peter LINKESCH; Libor VIKTORA; Jiri BOUDA; Pavel VLASAK a Jan KOSTUN. The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study. Cancers. BASEL: MDPI, 2024, roč. 16, č. 21, s. 1-12. ISSN 2072-6694. Dostupné z: https://doi.org/10.3390/cancers16213566.

@article{2455462,
   author = {Presl, Jiri and Havelka, Pavel and Weinberger, Vít and Ovesná, Petra and Fekete, Peter and Fruhauf, Filip and Jedryka, Marcin and Bystricky, Branislav and Strojna, Aleksandra and Volodko, Nataliya and Matylevich, Olga and Herboltova, Petra and Blecharz, Pawel and Kalist, Vladimir and Ehrlichová, Lucie and Stranik, Petr and Masak, Ladislav and Poncova, Renata and Czekanski, Andrzej and Chaloupkova, Barbora and Koblizkova, Michaela and Smoligova, Vendula and Hrabalova, Marketa and Jaksicova, Alena and Linkesch, Peter and Viktora, Libor and Bouda, Jiri and Vlasak, Pavel and Kostun, Jan},
   article_location = {BASEL},
   article_number = {21},
   doi = {https://doi.org/10.3390/cancers16213566},
   keywords = {ovarian cancer; tumor markers; CA125; HE4; recurrence detection},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study},
   url = {https://www.mdpi.com/2072-6694/16/21/3566},
   volume = {16},
   year = {2024}
}

TY  - JOUR
ID  - 2455462
AU  - Presl, Jiri - Havelka, Pavel - Weinberger, Vít - Ovesná, Petra - Fekete, Peter - Fruhauf, Filip - Jedryka, Marcin - Bystricky, Branislav - Strojna, Aleksandra - Volodko, Nataliya - Matylevich, Olga - Herboltova, Petra - Blecharz, Pawel - Kalist, Vladimir - Ehrlichová, Lucie - Stranik, Petr - Masak, Ladislav - Poncova, Renata - Czekanski, Andrzej - Chaloupkova, Barbora - Koblizkova, Michaela - Smoligova, Vendula - Hrabalova, Marketa - Jaksicova, Alena - Linkesch, Peter - Viktora, Libor - Bouda, Jiri - Vlasak, Pavel - Kostun, Jan
PY  - 2024
TI  - The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study
JF  - Cancers
VL  - 16
IS  - 21
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20726694
KW  - ovarian cancer
KW  - tumor markers
KW  - CA125
KW  - HE4
KW  - recurrence detection
UR  - https://www.mdpi.com/2072-6694/16/21/3566
N2  - Background: Ovarian, fallopian tube, and primary peritoneal cancers often share clinical characteristics and are typically diagnosed at advanced stages due to nonspecific symptoms. The utility of tumor markers, particularly CA125 and HE4, in the diagnosis and follow-up of these cancers remains an area of active investigation. Objectives: The CEEGOG (Central and Eastern European Gynecologic Oncology Group) OX-01 study aimed to evaluate HE4's role alongside CA125 in follow-up for advanced-stage ovarian, fallopian tube, and primary peritoneal cancers. It assessed the potential for detecting recurrence using marker elevation and imaging methods, examining the necessity of dynamic monitoring and current cut-off values' accuracy for early relapse detection. Methods: In this multicenter prospective cohort study, 117 eligible patients with Stage III-IV cancers were included. Patients had elevated CA125 or HE4 at diagnosis and achieved complete remission after first-line treatment. HE4 and CA125 levels were monitored every 3-4 months in the first two years and every six months thereafter. CT scans were performed if markers exceeded set thresholds or increased by over 20%. Results: During a median follow-up of 13.7 months, 73% of patients relapsed. Median HE4 levels were significantly higher in relapsed patients. A 10 IU/mL increase from baseline in CA125 had a sensitivity of 83% and specificity of 93%, while a 15 pmol/L increase in HE4 had a sensitivity of 74% and specificity of 92% for predicting relapse up to three months before CT scan detection. Conclusions: The study found that dynamic changes in HE4 and CA125 levels, rather than predefined cut-off values, are crucial for early relapse detection. These markers may offer a significant lead time over imaging, potentially enabling earlier intervention. Further research is needed to validate these findings.
ER  -

PRESL, Jiri; Pavel HAVELKA; Vít WEINBERGER; Petra OVESNÁ; Peter FEKETE; Filip FRUHAUF; Marcin JEDRYKA; Branislav BYSTRICKY; Aleksandra STROJNA; Nataliya VOLODKO; Olga MATYLEVICH; Petra HERBOLTOVA; Pawel BLECHARZ; Vladimir KALIST; Lucie EHRLICHOVÁ; Petr STRANIK; Ladislav MASAK; Renata PONCOVA; Andrzej CZEKANSKI; Barbora CHALOUPKOVA; Michaela KOBLIZKOVA; Vendula SMOLIGOVA; Marketa HRABALOVA; Alena JAKSICOVA; Peter LINKESCH; Libor VIKTORA; Jiri BOUDA; Pavel VLASAK a Jan KOSTUN. The Role of HE4 in the Follow-Up of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer-CEEGOG OX-01 Study. \textit{Cancers}. BASEL: MDPI, 2024, roč.~16, č.~21, s.~1-12. ISSN~2072-6694. Dostupné z: https://doi.org/10.3390/cancers16213566.

Přehled o publikaci